fluciclovine (18F)

DRUG2 trials

Sponsors

Blue Earth Diagnostics

Conditions

Prostate CancerProstatic Neoplasms

Phase 4

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

RecruitingNCT07569926

Blue Earth DiagnosticsProstate Cancer

Start: 2026-08-31End: 2032-12-31Target: 142Updated: 2026-09-08

Unknown Phase

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

CompletedNCT02443571

Blue Earth DiagnosticsProstatic Neoplasms

Start: 2015-01-31End: 2015-06-30Updated: 2018-12-19

Related Papers

Multisite experience of fluciclovine (<sup>18</sup>F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation.

Journal of Clinical Oncology2017-02-201 citations